Sage, Biogen Report Results From Phase 2 KINETIC 2 Study Of SAGE-324 (BIIB124) For Essential Tremor; Did Not Demonstrate Statistically Significant Dose-Response Relationship On Primary Endpoint

7/24/24 6:33:58 AM ET

$BIIB

$SAGE

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BIIB alert in real time by email

Sage, Biogen Report Results From Phase 2 KINETIC 2 Study Of SAGE-324 (BIIB124) For Essential Tremor; Did Not Demonstrate Statistically Significant Dose-Response Relationship On Primary Endpoint

Get the next $BIIB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BIIB
$SAGE

Company	Date	Price Target	Rating	Analyst
Sage Therapeutics Inc. $SAGE	11/21/2024	$4.00	Underperform → Sector Perform	RBC Capital Mkts
Biogen Inc. $BIIB	11/18/2024		Buy → Hold	Needham
Biogen Inc. $BIIB	11/15/2024		Peer Perform	Wolfe Research
Biogen Inc. $BIIB	11/14/2024	$190.00	Neutral	Citigroup
Biogen Inc. $BIIB	10/31/2024	$285.00 → $204.00	Overweight → Equal-Weight	Morgan Stanley
Biogen Inc. $BIIB	10/10/2024		Mkt Perform	Raymond James
Sage Therapeutics Inc. $SAGE	10/10/2024		Mkt Perform	Raymond James
Sage Therapeutics Inc. $SAGE	10/4/2024	$10.00 → $4.00	Outperform → Sector Perform	RBC Capital Mkts

More analyst ratings

$BIIB
$SAGE
Press Releases

Fastest customizable press release news feed in the world

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease
The Phase 2 DIMENSION Study did not meet its primary endpoint Dalzanemdor was generally well-tolerated; no new safety signals were observed Based on these data, the Company does not plan further development of dalzanemdor Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with Huntington's Disease (HD). In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary endpoint, the change from baseline on the Symbol Digit Modalities Test (SDMT) at Day 84. Analyses of secondary endpoints did not demonstr
11/20/24 6:30:00 AM ET
$SAGE
Biotechnology: Pharmaceutical Preparations
Health Care
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activityA greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on standard of care aloneSystemic Lupus Erythematosus is a chronic, debilitating autoimmune disease affecting multiple organ systems, primarily in women, for whom there is a significant need for additional treatment options BRUSSELS, Belgium and CAMBRIDGE, Mass., Nov. 19, 2024 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UC
11/19/24 1:00:14 AM ET
$BIIB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ", Biogen", )) announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab as a treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (Early Alzheimer's disease) who are apolipoprotein E ε4 (ApoE ε4)* non-carriers or h
11/14/24 1:29:00 PM ET
$BIIB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$BIIB
$SAGE
Financials

Live finance-specific insights

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
Achieved $11 million in ZURZUVAE® (zuranolone) collaboration revenue during the third quarter of 2024 (50% of the net revenue recorded by Biogen), representing 49% growth from the second quarter Sage and Biogen will not pursue further development of zuranolone in major depressive disorder (MDD) in the U.S. Topline data from the DIMENSION Study in Huntington's Disease (HD) expected late 2024 Cash, cash equivalents and marketable securities of $569 million as of September 30, 2024 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the third quarter ended September 30, 2024. "We are committed to harnessing the full potential of ZURZUVAE as
10/29/24 4:05:00 PM ET
$SAGE
Biotechnology: Pharmaceutical Preparations
Health Care
Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
Sage Therapeutics, Inc. (NASDAQ:SAGE), today announced that it will host a live webcast on Tuesday, October 29, 2024 at 4:30 p.m. ET to review third quarter 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments ind
10/15/24 6:30:00 AM ET
$SAGE
Biotechnology: Pharmaceutical Preparations
Health Care
Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
Achieved $7.4 million in ZURZUVAE™ (zuranolone) collaboration revenue during the second quarter of 2024 (50% of the net revenues recorded by Biogen), representing 19% growth from the first quarter More than 1,400 prescriptions shipped and delivered during the second quarter of 2024, nearly doubling from the first quarter Dalzanemdor (SAGE-718) topline data from the LIGHTWAVE (Alzheimer's Disease) and DIMENSION (Huntington's Disease) Studies expected in late 2024; primary endpoint for DIMENSION Study adjusted from HD-CAB composite to the Symbol Digit Modalities Test (SDMT) SAGE-324 did not meet the primary endpoint in participants with essential tremor (ET); Sage and Biogen terminated
7/31/24 4:05:00 PM ET
$SAGE
Biotechnology: Pharmaceutical Preparations
Health Care

$BIIB
$SAGE
Leadership Updates

Live Leadership Updates

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as Chief Medical Officer and Head of Medical Affairs, effective October 28, 2024. Dr. Quirk will report to Priya Singhal, M.D., M.P.H., Head of Development at Biogen. "At Biogen, scientific and medical leadership is the foundation for everything we do, and this is why we believe Dan will be a perfect fit to lead our Medical Affairs organization going forward," said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. "With his diverse background in medicine, public health, and business administration, and his extensive experience in medical affairs
10/29/24 8:00:00 AM ET
$BIIB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biogen Board Appoints Two New Independent Directors
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc. (NASDAQ:BIIB) Board of Directors (the "Board") today announced the appointments of two new independent directors, Lloyd B. Minor, M.D., effective October 1, 2024, and Sir Menelas (Mene) Pangalos, Ph.D., effective January 1, 2025. Dr. Minor is currently the Dean of the Stanford University School of Medicine and Vice President for Medical Affairs at Stanford University, and Prof Sir Pangalos was most recently Executive Vice President of Biopharmaceuticals R&D at AstraZeneca until his retirement in April 2024. "We welcome Lloyd and Mene to our Board as they add significant experience and proven track records in leading R&D
9/12/24 7:30:00 AM ET
$BIIB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biogen Appoints Monish Patolawala to its Board of Directors
CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company ("3M"), to the Company's Board of Directors (the "Board"), effective January 1, 2024. As an accomplished financial executive, Mr. Patolawala is qualified as an Audit Committee financial expert and may be asked to serve as a member of the Board's Audit Committee. "We are pleased to welcome Monish to the Board as the Company is advancing on its next chapter," said Caroline Dorsa, Chair of the Biogen Board of Directors. "Monish's deep financial expertise and diversified management experience at leadin
11/6/23 7:30:00 AM ET
$BIIB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Sage, Biogen Report Results From Phase 2 KINETIC 2 Study Of SAGE-324 (BIIB124) For Essential Tremor; Did Not Demonstrate Statistically Significant Dose-Response Relationship On Primary Endpoint

Chat with this insight

Recent Analyst Ratings for $BIIB$SAGE

$BIIB$SAGE Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Biogen Inc.

$BIIB$SAGE Market Insights

Live Market Insights

JP Morgan Downgrades Sage Therapeutics to Neutral, Lowers Price Target to $12

Baird Maintains Neutral on Sage Therapeutics, Lowers Price Target to $13

HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $25 Price Target

$BIIB$SAGE Press Releases

Fastest customizable press release news feed in the world

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

$BIIB$SAGE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Benecchi Christopher was granted 6,250 shares, increasing direct ownership by 34% to 24,737 units (SEC Form 4)

EVP Chief Legal Officer Alexander Susan H gifted 20,082 shares and received a gift of 20,082 shares, decreasing direct ownership by 39% to 31,601 units (SEC Form 4)

Head of Research Grogan Jane covered exercise/tax liability with 204 shares and converted options into 695 shares (SEC Form 4)

$BIIB$SAGE Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Rowinsky Eric K bought $101,256 worth of shares (455 units at $222.54), increasing direct ownership by 2% to 20,629 units (SEC Form 4)

$BIIB$SAGE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

SAGE Therapeutics upgraded by RBC Capital Mkts with a new price target

Biogen downgraded by Needham

Wolfe Research initiated coverage on Biogen

$BIIB$SAGE Financials

Live finance-specific insights

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates

Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress

$BIIB$SAGE Leadership Updates

Live Leadership Updates

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Biogen Board Appoints Two New Independent Directors

Biogen Appoints Monish Patolawala to its Board of Directors

$BIIB$SAGE SEC Filings

SEC Form 8-K filed by Sage Therapeutics Inc.

SEC Form 8-K filed by Sage Therapeutics Inc.

Biogen Inc. filed SEC Form 8-K: Regulation FD Disclosure

$BIIB$SAGE FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for VUMERITY issued to BIOGEN INC

FDA Approval for VUMERITY issued to BIOGEN INC

FDA Approval for VUMERITY issued to BIOGEN INC

Recent Analyst Ratings for
$BIIB
$SAGE

$BIIB
$SAGE
Large Ownership Changes

$BIIB
$SAGE
Market Insights

$BIIB
$SAGE
Press Releases

$BIIB
$SAGE
Insider Trading

$BIIB
$SAGE
Insider Purchases

$BIIB
$SAGE
Analyst Ratings

$BIIB
$SAGE
Financials

$BIIB
$SAGE
Leadership Updates

$BIIB
$SAGE
SEC Filings

$BIIB
$SAGE
FDA approvals